Matthew D Cheeseman

Matthew D Cheeseman is a notable inventor based in Sutton Coldfield, GB. He has made significant contributions to the field of pharmaceuticals, holding a total of 7 patents. His work primarily focuses on developing compounds that have therapeutic applications, particularly in the treatment of cancer and other proliferative diseases.

Latest Patents

Among his latest patents is a compound titled "Deuterated N-(5-(2,3-dihydrobenzo[b][1,4]dioxine-6-carboxamido)-2-fluorophenyl)-2-((4-ethylpiperazin-1-yl)methyl)quinoline-6-carboxamide." This invention relates to a pharmaceutical composition that includes compounds where at least one hydrogen atom has been substituted with a deuterium atom. The patent also discusses medical uses and methods of treatment involving these compounds. Another significant patent is for "Fused 1,4-dihydrodioxin derivatives as inhibitors of heat shock transcription factor 1." This invention focuses on compounds that inhibit heat shock factor 1 (HSF1) and their potential as therapeutic agents for treating and preventing proliferative diseases, including cancer.

Career Highlights

Matthew has worked with prominent organizations such as Cancer Research Technology Limited and the Institute of Cancer Research: Royal Cancer Hospital. His experience in these institutions has allowed him to contribute to groundbreaking research and development in cancer treatment.

Collaborations

Throughout his career, Matthew has collaborated with notable colleagues, including Keith Jones and Nicola Chessum. These partnerships have further enhanced his research and innovation in the pharmaceutical field.

Conclusion

Matthew D Cheeseman's innovative work and patents have made a significant impact in the realm of pharmaceuticals, particularly in cancer treatment. His contributions continue to influence the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.